Proteins are the workhorses of the cellular world, playing a critical role in virtually every biological process. From enzymes that power our metabolism to antibodies that fight off infection, proteins are the intricate machines that keep us alive. But what if we could design proteins with entirely new functions or optimize existing ones to be more efficient or effective? This is the ambitious goal of protein engineering, a field that has the potential to revolutionize everything from medicine and agriculture to materials science and biofuels.

One of the biggest challenges in protein engineering has been the complexity of the process. Proteins are complex three-dimensional structures, and even small changes in their amino acid sequence can have dramatic effects on their function. This has made it difficult to predict how changes in a protein’s sequence will affect its properties.

Cradle Bio, a young startup based in Cambridge, Massachusetts, is developing a new protein engineering platform that aims to make the process of designing and engineering proteins faster, easier, and more accessible. Cradle’s platform uses a combination of machine learning and computational modeling to predict the effects of mutations on protein structure and function. This allows scientists to rapidly design and test new protein variants without the need for time-consuming and expensive experimental methods.

One of the key advantages of Cradle’s platform is its ability to optimize multiple protein properties at the same time. Traditionally, protein engineering has focused on optimizing a single property, such as an enzyme’s activity or an antibody’s affinity for a target antigen. However, Cradle’s platform can be used to identify protein variants that are optimized for multiple properties simultaneously. This could be used to develop enzymes that are not only more active but also more stable or antibodies that are both highly specific and potent.

Cradle’s platform is already being used by a number of leading pharmaceutical and biotechnology companies. These companies are using Cradle to design new drugs, improve existing therapies, and develop novel biomaterials. For example, one company is using Cradle to design enzymes that can be used to break down pollutants in the environment. Another company is using Cradle to develop new antibodies for cancer immunotherapy.

The potential applications of Cradle’s technology are vast. By making protein engineering faster, easier, and more accessible, Cradle could help to accelerate the development of new drugs, diagnostics, and materials. Cradle’s technology could also lead to the development of entirely new products and applications that we can’t even imagine yet.

In addition to its technological innovation, Cradle Bio is also committed to making protein engineering more accessible to a wider range of scientists. The company offers a cloud-based platform that can be accessed by scientists from anywhere in the world. Cradle also offers a variety of educational resources, including workshops and tutorials, to help scientists learn how to use its platform.

Cradle Bio’s mission is to democratize protein engineering and make it a tool that can be used by scientists of all levels. By making protein engineering faster, easier, and more accessible, Cradle has the potential to revolutionize the field of biotechnology and usher in a new era of innovation.

Venkat

The post How Cradle Bio is Making Protein Design Accessible? appeared first on Healthcare CEO.

What is radiomics? About Quibim’s purpose

1. QP-Prostate®: This AI solution integrates with PACS systems to revolutionize prostate MRI readings. It provides precise, quantitative information, automates tasks, and ensures PI-RADS compliance, aiding radiologists in making more informed, standardized decisions.
2. QP-Brain®: Designed for brain diagnosis, QP-Brain® brings an innovative approach to volumetrics and White Matter Hyperintensity (WMH) Analysis. It offers objective analysis, precise volume, and morphometry calculations for disease classification and progression.
3. Quibim Precision®: This software offers a comprehensive range of applications, from disease detection to tracking treatment efficacy. It integrates seamlessly into clinical routines, allowing for pre-reporting results through AI in radiology. Quibim Precision® provides unique analysis suites tailored to various body organ systems.

Quibim collaborates with top-tier biopharma companies and healthcare institutions to glean insights into cancer and other diseases. Their technology supports the development of prognostic or predictive models, bridging the gap between research and personalized care.

Advertise

The post Quibim’s Impact on Medical Diagnostics: What is radiomics? appeared first on Healthcare CEO.

Innovations in Personalized Medicine

Kemet Group’s approach to healthcare is innovative and patient-centric. They specialize in connecting individuals with pharmacies capable of creating customized medications. This includes unique dosages, formulations, and solutions for out-of-stock medications, exclusively serving residents of Alberta. Their pioneering work has not gone unnoticed, as they have garnered several prestigious awards, including the 2021 MIT Solve Global Challenges Award for Health Security & Pandemics, a second place in the 2022 Zeton/CSChE Plant Design Competition, and recognition from the University of Alberta’s Faculty of Pharmacy & Pharmaceutical Science.

KemNet’s Role in Drug Reformulation

KemNet, a key component of Kemet Group, specializes in supplying pharmacies with premium reformulations of popular drugs tailored for specific patient groups. These reformulated products address various health issues, such as erectile dysfunction, hair growth, pain management, weight loss, and women’s health. Notably, their erectile dysfunction medications are acclaimed for being up to eight times faster than traditional alternatives. This innovative approach is not only beneficial for patients but also advantageous for pharmacies, contributing to their financial growth.

Founder’s Vision and Expertise

The vision behind KemNet is driven by Morẹ́nikẹ́ Ọláòṣebìkan, a licensed clinical pharmacist and pharmacy proprietor. Her role as a Clinical Academic Colleague at the Faculty of Pharmacy & Pharmaceutical Sciences, University of Alberta, highlights her commitment to advancing the field of pharmacy through innovative practices. Her leadership has been instrumental in developing KemNet as a platform for pharmacies to access these specialized medications.

Business Model and Patient Empathy

KemNet operates with a unique business model, positioning itself as the “Amazon” for customized medications. This model emphasizes empathy in patient care, leading to the development of medications that are not only effective but also enjoyable to use, with reduced side effects. The company’s focus on empathetic design in medication formulation, derived from Ọláòṣebìkan’s experience as a multi-pharmacy owner, has proven to be a successful strategy for both patient care and business growth.

Summary

Kemet Group, through KemNet, exemplifies the potential of personalized medicine in improving patient care and pharmacy practices. Their innovative approach to drug reformulation and distribution, combined with a strong emphasis on patient empathy, positions them as a trailblazer in the healthcare industry. With their unique solutions and patient-centered approach, Kemet Group is set to continue making significant contributions to personalized healthcare and pharmacy services.

Advertise

The post How Kemet Group is Changing the Face of Personalized Medicine? appeared first on Healthcare CEO.